Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study

BACKGROUND: Afatinib 30 mg has been proved to be with comparable efficacy but more tolerable than the dose of 40 mg for Asian patients with non-small cell lung cancer (NSCLC). This study aimed to investigate the clinical outcomes of afatinib at 30 mg/d in the treatment of advanced lung adenocarcinom...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Jie, Ye, Xuanting, Huang, Aimi, Qin, Ruoyan, Cai, Yuqing, Xue, Yiqian, Zhang, Shi, Wang, Weimin, Xiong, Liwen, Gu, Aiqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264103/
https://www.ncbi.nlm.nih.gov/pubmed/35813735
http://dx.doi.org/10.21037/jtd-22-507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264103/
https://www.ncbi.nlm.nih.gov/pubmed/35813735
http://dx.doi.org/10.21037/jtd-22-507

Ejemplares similares